Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
At Pure Med Spa, we support our clients with progress tracking and guidance to achieve the best possible outcomes
Regulatory watch Last reviewed Jul 1, 2026 Next review Jul 29, 2026 Evidence snapshot AOD-9604 was developed by Metabolic Pharmaceuticals (Australia) as a modified C-terminal fragment (residues 177-191) of human growth hormone, designed to retain lipolytic activity without growth-promoting effects
Numerous studies suggest that BPC-157 promotes angiogenesis, the formation of new blood vessels
Flexible payment options are available through Cherry financing
Microdosing semaglutide Some prescribers use doses below the standard starting point (less than 0.25 mg) for patients who are particularly sensitive to GLP-1 medications or who have a history of severe nausea with other medications
US$ 23.83
US$ 23.43
US$ 29.70
US$ 23.90
US$ 23.95
US$ 27.88
US$ 28.63
US$ 24.29
US$ 24.53
